度洛西汀
普瑞巴林
加巴喷丁
医学
指南
神经病理性疼痛
慢性疼痛
伤害
糖尿病神经病变
不利影响
疼痛阶梯
重症监护医学
物理疗法
麻醉
替代医学
药理学
内科学
糖尿病
病理
受体
内分泌学
癌症疼痛
出处
期刊:PubMed
日期:2023-03-01
卷期号:75 (3): 227-234
标识
DOI:10.11477/mf.1416202312
摘要
Antinociceptive therapy for chronic neuropathic pain is anecdotal in nature based on a physician's preference. However, evidence-based therapy is expected, following the chronic pain guideline established in 2021, supported by 10 pain-associated Japanese medical societies. The guideline strongly recommends the use of Ca2+-channel α2δ ligands (pregabalin, gabapentin, and mirogabalin) and duloxetine for pain relief. International guidelines also recommend administration of tricyclic antidepressants as first-line agents. Recent studies have described three classes of medicines that show comparable antinociceptive effects in painful diabetic neuropathy. Furthermore, a combination of first-line agents can improve efficacy. Antinociceptive medical therapy should be individualized based on the patient's condition and adverse effect profile of each medication.
科研通智能强力驱动
Strongly Powered by AbleSci AI